Does LEXX pay dividends?

Lexaria Bioscience Corp (LEXX) does not currently pay a regular dividend.

What is LEXX's market cap?

Lexaria Bioscience Corp (LEXX) has a market capitalization of $17.10M with a current stock price of $11.17.

Lexaria Bioscience Corp (LEXX)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$11.17

+0.82 (+7.92%)

Market Cap: $17.10M

Last updated: Sep 01, 2026 at 10:00 AM ET

Earnings

Performance (10Y)

Beat Rate

50%(10/20)

Avg Surprise

-10.71%

Upcoming Estimates

Aug 31, 2026

EPS Consensus$-3.79

Range$-3.79 - $-3.79

1 analysts

Revenue Consensus

$-130000

Range$-130000 - $-130000

1 analysts

Nov 30, 2026

EPS Consensus$N/A

Revenue Consensus

Range$0 - $0

0 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Nov 30, 2026Nov 26EST	-	N/A	-	-	-	-	-	-
Aug 31, 2026Aug 26EST	-	$-3.79	$-3.79 - $-3.79	-	-	1	-	-
May 31, 2026May 26	$-0.08	$-0.06	$-0.06 - $-0.06	-33.33%	Miss	1	1 0 30d	+61.9%
Feb 28, 2026Feb 26	$-0.06	$-0.07	$-0.07 - $-0.07	+14.29%	Beat	1	1 0 30d	+60.0%
Nov 30, 2025Nov 25	$-0.07	$-0.13	$-0.13 - $-0.13	+46.15%	Beat	1	1 0 30d	+56.3%
Aug 31, 2025Aug 25	$-0.14	$-0.15	$-0.18 - $-0.14	+9.68%	Beat	3	No revisions (30d)	+6.7%
May 31, 2025May 25	$-0.21	$-0.14	$-0.14 - $-0.14	-50.00%	Miss	0	No revisions (30d)	-61.5%
Feb 28, 2025Feb 25	$-0.15	$-0.16	$-0.16 - $-0.16	+6.25%	Beat	0	No revisions (30d)	-150.0%
Nov 30, 2024Nov 24	$-0.16	$-0.12	$-0.12 - $-0.12	-33.33%	Miss	0	No revisions (30d)	-23.1%
Aug 31, 2024Aug 24	$-0.15	$-0.11	$-0.11 - $-0.11	-36.36%	Miss	0	No revisions (30d)	-25.0%
May 31, 2024May 24	$-0.13	$-0.09	$-0.13 - $-0.05	-44.44%	Miss	3	No revisions (30d)	+64.9%
Feb 29, 2024Feb 24	$-0.06	$-0.10	$-0.10 - $-0.10	+40.00%	Beat	1	No revisions (30d)	+72.5%
Nov 30, 2023Nov 23	$-0.13	$-0.11	$-0.11 - $-0.11	-18.18%	Miss	1	1 0 30d	+56.7%
Aug 31, 2023Aug 23	$-0.12	$-0.13	$-0.17 - $-0.10	+7.69%	Beat	2	No revisions (30d)	+50.0%
May 31, 2023May 23	$-0.37	$-0.25	-	-48.00%	Miss	-	-	+9.8%
Feb 28, 2023Feb 23	$-0.22	$-0.22	$-0.22 - $-0.22	+0.86%	Beat	0	No revisions (30d)	+12.8%
Nov 30, 2022Nov 22	$-0.30	$-0.30	$-0.30 - $-0.30	+0.00%	Beat	0	No revisions (30d)	+14.3%
Aug 31, 2022Aug 22	$-0.24	$-0.21	$-0.21 - $-0.21	-14.29%	Miss	0	No revisions (30d)	-9.1%
May 31, 2022May 22	$-0.41	$-0.28	$-0.28 - $-0.28	-46.43%	Miss	1	No revisions (30d)	+18.0%
Feb 28, 2022Feb 22	$-0.25	$-0.21	$-0.21 - $-0.21	-19.05%	Miss	1	No revisions (30d)	-327.3%
Nov 30, 2021Nov 21	$-0.35	$-0.35	$-0.35 - $-0.35	+0.00%	Beat	0	No revisions (30d)	-52.2%
Aug 31, 2021Aug 21	$-0.22	$-0.23	$-0.23 - $-0.23	+4.35%	Beat	1	No revisions (30d)	-2100.0%
May 31, 2021May 21	$-0.50	N/A	-	N/A	Beat	-	-	-2400.0%
Feb 28, 2021Feb 21	$0.11	N/A	-	N/A	Beat	-	-	+1200.0%
Nov 30, 2020Nov 20	$-0.23	N/A	-	N/A	Beat	-	-	-2200.0%
Aug 31, 2020Aug 20	$-0.01	N/A	-	N/A	Beat	-	-	+0.0%
May 31, 2020May 20	$-0.02	N/A	-	N/A	Beat	-	-	-100.0%
Feb 29, 2020Feb 20	$-0.01	N/A	-	N/A	Beat	-	-	+0.0%
Nov 30, 2019Nov 19	$-0.01	N/A	-	N/A	Beat	-	-	+0.0%
Aug 31, 2019Aug 19	$-0.01	N/A	-	N/A	Beat	-	-	+50.0%
May 31, 2019May 19	$-0.01	N/A	-	N/A	Beat	-	-	+80.0%
Feb 28, 2019Feb 19	$-0.01	N/A	-	N/A	Beat	-	-	+50.0%
Nov 30, 2018Nov 18	$-0.01	N/A	-	N/A	Beat	-	-	+0.0%
Aug 31, 2018Aug 18	$-0.02	N/A	-	N/A	Beat	-	-	-100.0%
May 31, 2018May 18	$-0.05	N/A	-	N/A	Beat	-	-	-400.0%
Feb 28, 2018Feb 18	$-0.02	N/A	-	N/A	Beat	-	-	+91.7%
Nov 30, 2017Nov 17	$-0.01	N/A	-	N/A	Beat	-	-	+95.6%
Aug 31, 2017Aug 17	$-0.01	N/A	-	N/A	Beat	-	-	-
May 31, 2017May 17	$-0.01	N/A	-	N/A	Beat	-	-	-
Feb 28, 2017Feb 17	$-0.24	N/A	-	N/A	Beat	-	-	-
Nov 30, 2016Nov 16	$-0.23	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-2.13	EV/EBITDA	-7.22x
Price/FCF	-2.45x	FCF Yield	-40.75%
Profitability
Profit Margin	0.00%	Operating Margin	-3863.00%
ROE	-162.80%	ROIC	-199.82%
Financial Health
Debt/Equity	0.01x	Interest Coverage	N/A
Current Ratio	10.60x	Quick Ratio	10.60x
Trading Statistics
Beta	0.37	Avg Volume	76.85K
52-Week High	$12.89	52-Week Low	$0.37

Technical Indicators Dashboard

Moving Averages

SMA 10$11.16

SMA 20$8.92

SMA 50$8.52

SMA 200$10.93

EMA 10$10.61

EMA 20$9.73

EMA 50$9.09

EMA 200$10.93

MACD

Line: 0.97Signal: 0.75Hist: 0.22

ADX

ADX: 68.8+DI: 16.4-DI: 3.5

Aroon & PSAR

Aroon Up72.0

Aroon Down16.0

PSAR$12.84

Bollinger Bands

Upper Band$14.18

Lower Band$3.65

%B Position11806%(Upper)

Band Width0.71

RSI (14-Day)

Neutral

60.4

Momentum Oscillators

Stoch %K75.4

Stoch %D77.2

Williams %R-23.5

ROC (10d)8.2%

Momentum0.85

CCI (20d)63.5

MFI (14d)55.2

Volatility Measures

ATR (14d)$2.67(23.9%)

StdDev (20d)2.63

Hist Vol158.1%(High)

Volume Flow

VWAP$11.22

OBV-30.6M

AD Line27.5B

CMF (20d)0.295

Volume Metrics

Avg Vol (20d)77.7K

Vol Ratio4.6x(High)

VWMA (20d)$10.36

Pivot Points

R3$13.89

R2$13.18

R1$11.77

Pivot Point$11.06

S1$9.64

S2$8.93

S3$7.52

Advanced Oscillators

TSI23.51

Ultimate Osc51.1

KST484.59

Financial Data

Quarter	May 2026	Feb 2026	Nov 2025	Aug 2025	May 2025	Feb 2025	Nov 2024	Aug 2024	May 2024	Feb 2024	Nov 2023	Aug 2023
Total Revenue	$0	$20,000	$0	$174,000	$174,000	$174,000	$183,923	$84,000	$84,000	$145,000	$151,278	$-3,433
Cost of Revenue	$0	$26,568	$24,197	$21,398	$15,422	$17,809	$2,720	$16,370	$15,074	$15,931	$4,822	$56,173
Gross Profit	$0	$20,000	$-24,197	$174,000	$174,000	$174,000	$181,203	$84,000	$84,000	$145,000	$146,456	$-3,433

Operating Expenses	$1.99M	$1.47M	$1.57M	$2.86M	$3.92M	$2.93M	$2.87M	$2.29M	$1.83M	$813,005	$1.29M	$1.07M
R&D	$970,834	$475,388	$671,340	$1.88M	$2.72M	$1.69M	$1.95M	$967,206	$573,089	$245,779	$574,491	$500,406
SG&A	$1.02M	$996,515	$902,291	$980,477	$1.21M	$1.24M	$918,690	$1.32M	$1.25M	$567,226	$711,107	$566,673
Operating Income	$-1,993,804	$-1,451,903	$-1,573,631	$-2,688,597	$-3,750,421	$-2,751,012	$-2,690,707	$-2,203,064	$-1,742,919	$-668,005	$-1,139,142	$-1,070,512

Interest Income	$837	$1,769	$12	$2,816	$190	$0	$11	$6,993	$0	$0	$7,319	$0
Interest Expense	$0	$0	$22,081	$8,631	$40,185	$0	$15,921	$0	$41,393	$1	$45,896	$178,503
Income Before Tax	$-1,992,967	$-1,450,134	$-1,595,712	$-2,697,228	$-3,790,606	$-2,716,972	$-2,706,628	$-2,186,571	$-1,784,312	$-652,733	$-1,185,038	$-1,249,015
Income Tax Expense	$14	$2,598	$1,791	$0	$0	$3,760	$0	$0	$-2,623	$-3,195	$40,181	$-9,696

Net Income	$-1,991,202	$-1,449,979	$-1,595,007	$-2,695,838	$-3,789,092	$-2,713,212	$-2,703,699	$-2,184,790	$-1,781,693	$-649,539	$-1,179,323	$-1,239,319

EBITDA	$-1,992,967	$-1,431,033	$-1,578,846	$-2,675,830	$-3,759,651	$-2,714,695	$-2,673,433	$-2,194,331	$-1,769,238	$-636,801	$-1,156,260	$-1,178,087
EBIT	N/A	$-1,450,134	$-1,595,712	$-2,697,228	$-3,790,606	$-2,716,972	$-2,706,628	$-2,186,571	$-1,784,312	$-652,732	$-1,185,038	$-1,249,015

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about LEXX

News

DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Lexaria Bioscience Corp. announced significant absorption improvements for amycretin and retatrutide using its DehydraTECH 3.0 platform in a recent animal study. The DHT3.0-amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study, while the DHT3.0-retatrutide tablet formulation increased drug absorption by up to 4,552%. These findings support Lexaria's efforts to partner for oral delivery of next-generation GLP-1 drugs.

Investing News Network•Aug 24, 2026 2:14 PM8/24/26•

Neutral

DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Lexaria Bioscience Corp. announced significant absorption improvements for amycretin and retatrutide using its DehydraTECH 3.0 platform in a recent animal study. The study showed that DHT3.0 formulations more than doubled the absolute bioavailability of amycretin and dramatically increased retatrutide absorption by as much as 4,552% compared to earlier versions. These findings highlight DehydraTECH's potential for enhancing oral delivery of next-generation GLP-1 drugs and support Lexaria's strategic partnering efforts.

Yahoo Finance•Aug 24, 2026 8:10 AM8/24/26•

Bullish

Lexaria Bioscience regains Nasdaq compliance, stock to remain listed

Lexaria Bioscience Corp. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. As a result, the previously scheduled hearing regarding the deficiency has been canceled, and Lexaria's common stock will continue to be listed on The Nasdaq Capital Market. This ensures the company avoids delisting due to the previous non-compliance issue.

Investing.com•Aug 18, 2026 10:40 AM8/18/26•

Bullish

Form 8K LEXARIA BIOSCIENCE CORP. For: 17 August By Investing.com

This article reports that Lexaria Bioscience Corp. filed a Form 8K on August 17. The filing is an important regulatory disclosure for investors and the market. The article is from Investing.com and was published on August 17, 2026, at 17:46.

Investing.com Nigeria•Aug 18, 2026 10:40 AM8/18/26•

Neutral

Lexaria Bioscience regains Nasdaq compliance, stock to remain listed By Investing.com

Lexaria Bioscience Corp. announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its stock will continue to be listed and traded on The Nasdaq Capital Market. The company received confirmation from a Nasdaq Hearings Advisor, leading to the cancellation of a previously scheduled deficiency hearing. This resolution follows an earlier notice from Nasdaq regarding its non-compliance with the minimum bid price rule.

Investing.com India•Aug 17, 2026 5:24 PM8/17/26•

Bullish

Frequently Asked Questions About LEXX

Does LEXX pay dividends?: Lexaria Bioscience Corp (LEXX) does not currently pay a regular dividend.
What is LEXX's market cap?: Lexaria Bioscience Corp (LEXX) has a market capitalization of $17.10M with a current stock price of $11.17.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In